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Abstract: The Visual Simpliﬁ  ed Respiratory Questionnaire (VSRQ) was designed to assess 
health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease 
(COPD). It contains eight items: dyspnea, anxiety, depressed mood, sleep, energy, daily activities, 
social activities and sexual life. Psychometric properties were assessed during a clinical trial 
that evaluated the impact of tiotropium on HRQoL of COPD patients. These included the 
determination of structure, internal consistency reliability, concurrent validity with the St George’s 
Respiratory Questionnaire (SGRQ), test – retest reliability, clinical validity and responsiveness 
to change over two weeks. Minimal important difference (MID) was calculated; cumulative 
response curves (CRC) were based on the dyspnea item. Psychometric analyses showed that 
VSRQ structure was unidimensional. The questionnaire demonstrated good internal consistency 
reliability (Cronbach’s alpha = 0.84), good concurrent validity with SGRQ (Spearman = −0.70) 
and clinical validity, good test-retest reproducibility (ICC = 0.77), and satisfactory responsiveness 
(standardized response mean = 0.57; Guyatt’s statistic = 0.63). MID was 3.4; CRC median value 
of the ‘minimally improved’ patients was 3.5. In conclusion, VSRQ brevity and satisfactory 
psychometric properties make it a good candidate for large studies to assess HRQoL in COPD 
patients. Further validation is needed to extend its use in clinical practice.
Keywords: chronic obstructive pulmonary disease, VSRQ, SGRQ, health-related quality of 
life, minimal important difference
Introduction
COPD adversely impacts emotional and physical aspects such as fatigue and muscle 
weakness, sleep and mood, exacerbations.1–5 Beside smoking cessation, symptom 
relief and improvement in Health-Related Quality of Life (HRQoL) are major goals of 
currently available treatments and key points in patients’ management.6,7 Nowadays, 
HRQoL is considered as a major endpoint in clinical trials for new COPD drugs, 
together with lung function parameters such as forced expiratory volume in one 
second (FEV1).
Generic instruments measuring HRQoL such as the Quality of Well-Being Scale 
(QWB) and the Sickness Impact Proﬁ  le (SIP) may be used in COPD patients but showed 
a low sensitivity.8 Amongst the disease-speciﬁ  c questionnaires,9–12 the St George’s 
Respiratory Questionnaire (SGRQ) evaluates patient’s health status, including symp-
toms, activities and psychosocial impacts of COPD and asthma.13,14 It has been used 
extensively in clinical trials; yet, its length of completion limits its adoption as a tool 
for routine use. The Chronic Respiratory Questionnaire (CRQ) is used in patients 
with chronic respiratory diseases15,16 and has shown high sensitivity to changes, but International Journal of COPD 2009:4 10
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the individualization of its dyspnea domain likely increases 
its complexity for both patients and interviewers.17 Shorter 
questionnaires such as the Airways Questionnaire 20 (AQ20) 
measure HRQoL in patients with COPD and asthma, but 
demonstrate poor discriminative power.18
In the landscape of HRQoL assessment in COPD, there is 
a need for questionnaires speciﬁ  cally designed and validated 
for an easy assessment in outpatient settings, real-life studies 
and/or routine care of the individual. The Visual Simpliﬁ  ed 
Respiratory Questionnaire (VSRQ) was developed in order 
to offer an alternative to the already existing reference instru-
ments to researchers and clinicians. It quickly measures and 
interprets HRQoL in COPD patients. In the present paper, we 
describe the VSRQ validation as well as its responsiveness 
and minimal important difference (MID) in a clinical trial 
setting designed to evaluate the effect of tiotropium treatment 
on HRQoL in COPD.19 The SGRQ was taken as a reference 
for comparison.
Methods
Study design and patients’ population
The VSRQ was initially developed by a team of three pulmo-
nary physicians involved in COPD management (TP, ABT, 
and JMG), and a specialist of HRQoL (BA), after a thorough 
and extensive analysis of existing generic and COPD speciﬁ  c 
questionnaires. Selection of questions was further based 
on two preliminary studies of questionnaires with ﬁ  ve to 
eight visual analog scales.20. Formulation of questions was 
further reﬁ  ned after ten face-to-face comprehension tests 
with COPD patients. Its ﬁ  nal structure contains eight items 
covering dyspnea, state of anxiety, depressed mood, quality 
of sleep, energy, daily activities, social activities and sexual 
life. Each question is administered separately by the physi-
cian, through a fenestrated cardboard, and is assessed on a 
10-cm long horizontal numerical rating scale that ranged 
from 0 to 10, with gradation lines every 1 cm; lower scores 
indicate higher impact on patients’ HRQoL. Labels of each 
extremity are speciﬁ  c to the item.
The VSRQ was included in a clinical trial that aimed to 
determine the impact of tiotropium on HRQoL in patients 
with mild to severe COPD, as deﬁ  ned by the 1995 American 
Thoracic Society criteria.19 Patients with very severe COPD 
requiring long term oxygen therapy were excluded. Com-
plete description of the criteria patients had to meet to be 
eligible is found in the treatment-effect article.19 The study 
was a French multicenter, nine-month, double blind, placebo 
controlled-trial. Physicians administered the VSRQ and the 
SGRQ at screening visit (V1), baseline-visit (14 days, V2), 
three-month visit (V3), six- and nine-month visits. At V1, 
physicians also completed a case report form and established 
a global health assessment for each patient. Spirometric 
measures were performed at each visit, and included FEV1, 
forced vital capacity (FVC), FEV1/FVC and inspiratory 
capacity (IC).19 Trial medication (tiotropium or placebo) 
was introduced at V2. Design and rules regarding treatment 
protocol during the study are fully described in the treatment-
effect paper.19
Reliability and validity of the questionnaire were deter-
mined at V2, on the cross-sectional population, ie, all subjects 
for whom VSRQ and SGRQ questionnaires were completed 
at all visits, and for which at least 50% of all VSRQ and 
SGRQ items were ﬁ  lled out at V1 (Figure 1). In order to 
prevent a learning effect bias, the cross-sectional population 
was randomly split into a 2:1 ratio: 2/3 of the patients were 
included in the ﬁ  nalization step of the VSRQ (‘ﬁ  nalization 
set’ population), and 1/3 in the validation step (‘validation 
set’ population).21 The responsiveness of the questionnaire 
was assessed on the longitudinal population (patients for 
whom VSRQ and SGRQ were completed at V2 and V3 and 
were assessable, ie, at least 50% of the items completed) 
(Figure 1). The reproducibility was measured on patients 
with assessable VSRQ and SGRQ at V2 and a clinically 
stable status (ie, no COPD exacerbation) between V1 and V2 
(Figure 1).
Statistical and psychometric validation 
methodology
Validity is the degree to which the instrument measures what 
it is supposed to measure.22,23 Several types of validity are 
distinguished. Principal Component Analysis (PCA) with 
Varimax Rotation was used to test the unidimensional struc-
ture of the questionnaire.24 The ﬁ  nal structure of the VSRQ 
was evaluated by performing a multitrait analysis describing 
item convergent validity. Correlation between each item 
and the dimension was satisfactory if it achieved  0.40 
for item convergent validity criterion.25 Floor and ceiling 
effects were determined in order to assess the ability of the 
scores to evaluate all severity levels in the study population. 
Concurrent validity consists in analyzing correlation levels 
between dimensions of the studied questionnaire and those 
of a questionnaire measuring similar concepts. A newly 
developed questionnaire should display a moderate correla-
tion (0.40 to 0.70) with a well-established tool to conclude 
to good concurrent validity but no redundancy;22 Spearman 
correlation coefﬁ  cients were calculated between VSRQ 
and SGRQ. Clinical validity evaluates the extent to which International Journal of COPD 2009:4 11
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a questionnaire is able to detect variability among patients 
with different clinical severity levels. Patients’ clinical health 
status was deﬁ  ned based on the physician global assessment 
at V1 prior to the pulmonary function testing. This resulted 
in their allocation into four groups: “poor”, “fair”, “good” 
and “excellent”. Patients’ health status evaluation was based 
on the need for concomitant therapy, number and severity 
of exacerbations, severity of cough, exercise limitation, and 
physical ﬁ  ndings (eg, wheezing).
In addition to descriptive analyses, nonparametric 
Kruskal-Wallis test (when comparing three groups or more of 
patients) or Mann-Whitney Wilcoxon test (when comparing 
two groups of patients) were used for group comparisons.
Reliability is the degree to which an instrument is free 
from random error; it is evaluated by measuring internal con-
sistency reliability and reproducibility.26 Internal consistency 
reliability refers to the homogeneity of the items of the scale 
and was assessed by Cronbach’s alpha coefﬁ  cient determi-
nation.27 A coefﬁ  cient  0.70 was considered satisfactory.24 
Reproducibility establishes the stability of an instrument over 
time in a stable population.23 Intraclass correlation coefﬁ  -
cients (ICC) and concordance correlation coefﬁ  cients (CCC) 
were calculated to measure the reproducibility of VSRQ and 
SGRQ between V1 and V2.28,29 Patients were considered 
stable if they did not experience an exacerbation episode 
over the 14 days. For group comparison, coefﬁ  cient  0.70 
was considered satisfactory.24
Responsiveness is the instrument’s ability to detect clini-
cally important change over time,30 and is usually described 
by the effect-size (ES), standardized response mean (SRM) 
and Guyatt’s statistic.30,31 Changes are interpreted as “low 
change” (values close to 0.20), “moderate change” (values 
close to 0.50), and “important change” (values close 
to 0.80).32 The assessment of a signiﬁ  cant change from 
zero was made by performing the Wilcoxon signed-rank 
test. The ability of the questionnaire to reﬂ  ect underlying 
change was deﬁ  ned over 3 months (between V2 and V3). 
At V3, patients rated changes for each of the eight concepts 
covered by the VSRQ using the Overall Treatment Effect 
(OTE) questionnaire together with the VSRQ completion. 
When patients stated a health improvement or deterioration, 
they further reported the level of change on a 15-point rating 
scale, from –7 (“a great deal worse”) through 0 (“no change”) 
to +7 (“a great deal better”).33 According to their responses 
to the OTE, patients were allocated into three subgroups: 
“worsened”, “stable” and “improved”.
The MID, for the clinical interpretation of change 
in HRQoL scores, was calculated according to the 
Total population
(n = 664)
(n = 647)
(n = 636)
(n = 420) (n = 216) (n = 535)
(n = 432)
(n = 373)
VSRQ and SGRQ
Completed at all visits
Eligible population
Assessable VSRQ and SGRQ at V1
(at least 50% of items completed)
Assessable VSRQ and SGRQ between V2
and V3 (at least 50% of items completed)
Cross-sectional population
2/3 1/3
Assessable VSRQ and SGRQ
at V2 and/or stable clinical
status between V1 and V2
‘Finalization set’
population population on
‘Validation set’ ‘Reproducibility’
population
‘Responsiveness’
analysis population
analysis population
Completed
OTE at V3
Eligible responsiveness
Figure 1 Composition and deﬁ  nition of the populations included in the analyses.International Journal of COPD 2009:4 12
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methodology developed by Juniper and colleagues.33,34 
Brieﬂ  y, from their responses to the OTE, patients were 
classiﬁ  ed based on the 15-point scale as follows: patients 
with scores of –7 to –2 were considered as having a “wors-
ened” health status, patients with scores of –1 to 1 as “sta-
ble”, patients with scores of 2 to 3 as “minimally improved”, 
patients with scores of 4 to 5 as “quite improved”, and 
patients with scores of 6 to 7 as “highly improved”. Based 
on the dyspnea OTE scores, cumulative response curves 
were drawn for each of the groups described above. In 
parallel, a regression was performed between the changes in 
VSRQ and SGRQ global score used as an anchor, in order 
to estimate the change in VSRQ score corresponding to 
the MID of the SGRQ of 4 that was previously determined 
by Jones.35
Correlations between FEV1 expressed as a percentage of 
predicted value (FEV1 % pred) and VSRQ or SGRQ were 
assessed at V1 by calculating Spearman coefﬁ  cients.
Main analyses were performed using SAS software 
(Statistical Analysis System, version 8.02; SAS Inc., Cary, 
NC, USA). The threshold for statistical signiﬁ  cance was set 
up at 5%.
Results
Patients’ population
Of the 664 patients recruited, 636 had completed assessable 
questionnaires at V1 and constituted the cross-sectional 
population. The overall mean age of patients at V2 was 
64.3 years (± 10.0); the majority were male (84.9%); 72.2% 
were ex-smokers, 27.4% were current smokers and 0.3% 
never smoked (0.1% were missing data [MD]), with a mean 
of 43.1 ± 21.5 pack-years. COPD was diagnosed for eight 
years in average. According to physicians’ global assessment, 
the majority of  patients had “fair” (43.1%) to “good” (42.6%) 
health status. Mean FEV1 % pred was 46.81; FVC (L), 2.49; 
FEV1/FVC %, 54.95 and IC, 2.11, for patients randomized 
at baseline and receiving a treatment. Additional spirometric 
measures are described in a treatment-effect article.19
Quality of completion of the VSRQ
The return rates were very high at each visit, with 69% (V3) 
to 96% (V1) VSRQ received (percentages based on overall 
recruited population, n = 664). Similar rates were found for 
SGRQ (74% received at V3; 97% at V1). Percentages of MD 
were low for VSRQ, ranging from 1.4% to 9.9% (item 8, 
“embarrassment in your sexual life”) MD within V1 to V3 
visits. Higher percentages were reported for the SGRQ, with 
4.5% to 6.5% MD.
VSRQ ﬁ  nalization
Due to MD in the retrieved questionnaires, 382 patients out 
of the 420 were considered for the ﬁ  nalization study of the 
questionnaire (‘ﬁ  nalization set’). Following PCA, one factor 
was retained by the Mineigen criterion (Eigenvalue   1), 
which accounted for 51% of the total variance, indicating 
that a global score could therefore be calculated (Table 1). 
A multitrait analysis was performed. Item-scale correlation 
coefﬁ  cients were greater than 0.40, ranging from 0.47 to 0.73. 
No ﬂ  oor effect and no ceiling effect were reported (0.0% 
and 0.3%, respectively). Cronbach’s alpha coefﬁ  cient for 
the global score was 0.85.
VSRQ validation and scoring
PCA with the ‘validation set’ population (n = 216 patients) 
conﬁ  rmed the VSRQ unidimensionality, with the single 
factor accounting for 46% of the total variance. Item con-
vergent validity criterion of the global score was conﬁ  rmed. 
No ﬂ  oor effect and no ceiling effect were reported (0.0% and 
0.5%, respectively); Cronbach’s alpha for the global score 
was good (0.82).
The global score of the VSRQ was calculated as the sum 
of the eight item scores, when all items were completed and 
ranged from 0 to 80, with higher scores indicating better 
HRQoL condition. Scores were respectively 44.58 ± 15.96 
(n = 578; 58 MD) and 49.72 ± 16.44 (n = 373; 59 MD) at 
screening and V3 visits. Scores of SGRQ were calculated 
as recommended by the authors13,14 with higher scores indi-
cating lower HRQoL. Scores were 47.18 ± 17.44 (n = 623; 
13 MD) and 41.25 ± 18.64 (n = 421; 11 MD) at V1 and V3, 
respectively.
Psychometric properties of the VSRQ
The following analyses were performed on the total cross-
sectional population (n = 636), except wherever speciﬁ  ed.
Reliability
Cronbach’s alpha coefﬁ  cient of the VSRQ global score was 
0.84, showing good internal consistency reliability of the 
questionnaire. Cronbach’s alpha of the SGRQ total score 
was low (0.46), but values were good for each of the three 
SGRQ sub-scores (0.69 to 0.83).
The test-retest reliability of the VSRQ and the SGRQ was 
measured between V1 and V2, with stable patients. ICC and 
CCC values ranged from 0.50 (impact on social life item) to 
0.74 (impact on sexual life item) for the VSRQ. Both ICC and 
CCC values exceeded the 0.70 threshold for the global score 
of VSRQ (ie, 0.77) (Table 2). The Wilcoxon signed-rank International Journal of COPD 2009:4 13
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test was not signiﬁ  cant (p = 0.45), which demonstrated that 
scores remained stable over the two weeks. Similarly, ICC 
and CCC values were higher than 0.70 for the total score 
of SGRQ (0.86), with values for sub-scores ranging from 
0.71 (symptoms sub-score) to 0.83 (impacts sub-scores). 
Changes to zero were not signiﬁ  cant (p = 0.27).
Validity
Based on physician’s global assessment of patients’ health 
at V1, patients were ascribed into the group “poor”, “fair”, 
“good” or “excellent”. Distribution of the VSRQ global score 
according to each of these groups is reported in Table 3. 
Differences in VSRQ scores across clinical severity groups 
were highly signiﬁ  cant (p   0.0001). As patients’ global 
health improved, VSRQ scores increased. As patients’ 
global health improved, SGRQ scores decreased, with score 
differences between severity groups reaching statistical 
signiﬁ  cance (p   0.0001).
Spearman correlation coefficient value between 
VSRQ total score and FEV1 % pred at V1 was 0.16; coef-
ﬁ  cient was the highest for dyspnea item of VSRQ, with a 
value of 0.22. Correlation between SGRQ global score and 
FEV1 % pred was also weak (−0.26).
As presented in Table 4, overall, correlations between 
VSRQ items and SGRQ sub-scores were moderate 
(Spearman coefﬁ  cients ranging from −0.26 to −0.59) and 
were higher between VSRQ global score and SGRQ total 
score (Spearman coefﬁ  cient correlation =  −0.70). Correla-
tions between VSRQ global score and the three SGRQ sub-
scores ranged from −0.50 to −0.68. Correlation between 
VSRQ and SGRQ changes between V2 and V3 was satisfac-
tory (rho: −0.47).
Responsiveness
SRM and Guyatt’s statistic indicated a good responsiveness 
of VSRQ global score (0.57 and 0.63 for the ‘improved’ 
group, respectively) (Figures 2C and 2B); slightly lower ES 
(0.40) was observed (Figure 2A). Only change in scores in 
the ‘improved’ group was signiﬁ  cantly different from zero 
(p   0.0001). For SGRQ total score, Guyatt’s statistic and 
SRM demonstrated high responsiveness (−0.84 and −0.75, 
respectively; Figures 2B and 2C), while ES indicated 
Table 1 Factor pattern of the VSRQ resulting from the Principal Component Analysis (PCA) 
Itemsa (Anchors of numerical rating scale) Correlations resulting from PCA
Have you been hindered by your shortness of breath? (0: Extremely – 10: Not at all) 0.75779
Because of your respiratory problem, have you had difﬁ  culties in performing your usual 
daily activities (eg house cleaning, gardening)? (0: Extremely – 10: Not at all)
0.77796
Have your respiratory problems hindered your social life and your relations with others, 
your family, your friend or acquaintances? (0:   All the time – 10: Never)
0.70807
The quality of your sleep was (0:   Very poor – 10: Excellent) 0.61581
Have you had pleasure with the same things at other times? (0: No, much less – 10: Yes) 0.81900
Have you felt energetic? (0: Never – 10:   All the time) 0.79833
Were you worried about your health? (0:   All the time – 10:   Almost never) 0.57470
Have your respiratory problems hindered your sexual life? (0: Extremely – 10: Not at all) 0.60476
Notes: aItems were translated into English for the purpose of publishing, but did not follow a linguistic validation process (ie there has been no process of iterative forward 
and backward translation; this English version is therefore not suitable for use); Recall period is one month.
Abbreviation: VSRQ, Visual Simpliﬁ  ed Respiratory Questionnaire.
Copyright © 2008, Boehringer Ingelheim International. All rights reserved. Any use or reproduction of this questionnaire without written authorization prohibited.
Table 2 Reproducibility by test-retest of VSRQ and SGRQ between screening (V1) and baseline visits (V2), ie, two weeks, in stable 
patients (N = 535)
Questionnaires N Mean change
in scores (SD)
ICC CCC p-value sign
rank test
VSRQ global scorea 455 0.32 (11.1) 0.77 0.77 0.45
SGRQ total scorea 515 0.37 (9.30) 0.86 0.86 0.27
Notes: a80 missing data for VSRQ; 20 missing data for SGRQ.
Abbreviations: CCC, concordance correlation coefﬁ  cient; ICC, intraclass correlation coefﬁ  cient; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire; 
VSRQ, Visual Simpliﬁ  ed Respiratory Questionnaire.International Journal of COPD 2009:4 14
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moderate responsiveness (−0.52; Figure 2A). Change in 
scores was signiﬁ  cant for all three groups, with p-values 
varying from  0.0001 to 0.05.
In patients who have experienced a health status 
improvement, the overall change in VSRQ global score 
was 6.7; in patients who reported deterioration, the 
change in scores was −0.8, reflecting that VSRQ global 
mean score increased as patients’ health status improved 
(Table 5). A similar pattern was observed for SGRQ: as 
global rating of change improved, a decrease was observed 
in the SGRQ total mean score, indicating a better health 
condition.
Deﬁ  nition of the MID
Change in VSRQ score corresponding to the MID was 
assessed from the OTE breathlessness scale (corresponding 
to the dyspnea item). The MID was then determined as the 
mean change in the ‘improved’ group on this scale (OTE 
score = +2 or +3) and was 3.4. In parallel, a MID value of 
3.2 for VSRQ was determined from the regression analysis 
between VSRQ global score and SGRQ total score.
The median response of the “minimally improved” group 
determined from the cumulative response curves that were 
drawn based on the dyspnea OTE was 3.5 (Figure 3).
Discussion
Although HRQoL instruments have been widely used for 
studying COPD impacts on patients’ HRQoL, none of them 
combine brevity, comprehensive coverage of all dimensions 
of HRQoL (ie, physical function, psychological state, social 
interaction, and somatic sensation, as deﬁ  ned by Schipper and 
colleagues) and COPD speciﬁ  city altogether.9,11,15,18,36 VSRQ 
is a new disease-speciﬁ  c tool assessing the impact of COPD 
on patients’ HRQoL in routine practice and large real-life 
studies. It comprises only eight items covering dyspnea, state 
of anxiety, depressed mood, quality of sleep, energy, daily 
activities, social activities and sexual life HRQoL domains. 
Its average length of completion is 3 min, 20 sec, much lower 
than the time required for the two widely used instruments 
SGRQ or CRQ (10 to 25 minutes).13–15 VSRQ recall period 
is one month, similar to that reported for SGRQ.13,14
The VSRQ showed fair psychometric properties, 
comparable to the SGRQ regarding most validation criteria. 
The correlations between the questionnaires’ scores indicated 
good level of consistency between the concepts measured by 
VSRQ and SGRQ, but no redundancy (correlations of −0.70 
between VSRQ global score and SGRQ total score). The 
VRSQ global score was found to be more strongly correlated 
with the SGRQ activities and impacts sub-scores than with 
Table 4 Spearman correlation coefﬁ  cients between VSRQ and SGRQ at screening visit (n = 636) (p   0.0001)
Shortness of 
breath
Daily activities 
impact
Social life 
impact
Sexual life 
impact
Pleasure 
impact
Energy 
impact
Worry 
impact
Sleep 
impact
VSRQ total 
score
Symptoms sub-score −0.43 −0.40 −0.31 −0.26 −0.40 −0.39 −0.30 −0.32 −0.50
Impacts sub-score −0.48 −0.55 −0.51 −0.38 −0.56 −0.51 −0.39 −0.42 −0.68
Activities sub-score −0.43 −0.56 −0.40 −0.35 −0.52 −0.47 −0.26 −0.28 −0.58
SGRQ total score −0.52 −0.59 −0.50 −0.38 −0.59 −0.54 −0.38 −0.41 −0.70
Abbreviations: SGRQ, St George’s Respiratory Questionnaire;   VSRQ, Visual Simpliﬁ  ed Respiratory Questionnaire.
Table 3 Score distribution for VSRQ and SGRQ according to global health patient groups as assessed by physicians at V1 (N = 636)
Physician’s global assessment p-valueb
 Poor Fair Good Excellent
VSRQ
 N a 48 248 248 33
   Global score (mean ± SD) 31.9 ± 14.3 41.7 ± 14.5 48.1 ± 15.7 57.6 ± 14.0  0.0001
SGRQ
 N a 54 271 263 34
  Total score (mean ± SD) 63.8 ± 15.2 49.7 ± 15.7 43.2 ± 16.9 31.8 ± 14.3  0.0001
Notes: a59 missing data for VSRQ; 14 missing data for SGRQ; bKruskal-Wallis test.
Abbreviations: SGRQ, St George’s Respiratory Questionnaire;   VSRQ, Visual Simpliﬁ  ed Respiratory Questionnaire.International Journal of COPD 2009:4 15
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the symptoms sub-score, which agrees with the fact that 
VSRQ was developed as a HRQoL tool rather than a symp-
tom assessment tool. In the same way, VSRQ items about 
sexual life, emotional and sleep impacts were the most weakly 
correlated with the SGRQ total score, which was expected 
as these former VSRQ items measure concepts that are not 
explicitly covered by the SGRQ. VSRQ demonstrated good 
reliability, with good internal consistency of each individual 
item between one to each of the others. Reproducibility analy-
ses concluded to the stability of the VSRQ over 2 weeks, 
although somewhat slightly lower than the one observed for 
the SGRQ; yet it remained satisfactory and comparable to 
that of the recently self-administered modiﬁ  ed version of the 
CRQ.17 VSRQ also showed as good ability as the SGRQ in 
discriminating between groups of patients presenting different 
levels of COPD severity, thus demonstrating that in spite of 
its brevity, the VSRQ was clinically valid. One could question 
the possible interference between VSRQ administration and 
health status rating by the physician. However, it has been 
recently reported that physician’s rating of patient’s health sta-
tus was only marginally inﬂ  uenced by patient’s own self-rated 
health.37 In order to consolidate these clinical ﬁ  ndings, it 
should be interesting to validate each individual item of the 
VSRQ by comparing it with its corresponding physiological 
measures, eg, dyspnea item with lung hyperinﬂ  ation, daily 
activities item with the 6-min walking distance.
The responsiveness of the VSRQ over 3 months, though 
slightly lower than the SGRQ especially in detecting 
deterioration, was satisfactory, indicating that the VSRQ 
enabled to report modiﬁ  cations in patients’ COPD medical 
condition that may have occurred during this time. Compa-
rable data were recently reported for both CRQ and SGRQ 
in different study settings,38,39 and one should point out that 
the responsiveness property of disease-speciﬁ  c question-
naires widely differ between clinical studies according to 
patients’ clinical characteristics.40 The number of worsened 
patients with complete VSRQ was low (n = 39), which 
might have compromised the sensitivity analysis in this 
subgroup. The change in SGRQ score was also of borderline 
signiﬁ  cance in these patients.
E
f
f
e
c
t
 
S
i
z
e
S
t
a
n
d
a
r
d
i
s
e
d
 
R
e
s
p
o
n
s
e
 
M
e
a
n
G
u
y
a
t
 
S
t
a
t
i
s
t
i
c
VSRQ Global
Score
VSRQ Global
Score
VSRQ Global
Score
SGRQ Total
Score
SGRQ Total
Score
SGRQ Total
Score
Worsened Stable Improved
AB C
1
0.6
0.8
0.4
0.2
−0.2
0
−0.4
−0.6
−0.8
−1
1
0.6
0.8
0.4
0.2
−0.2
0
−0.4
−0.6
−0.8
−1
1
0.6
0.8
0.4
0.2
−0.2
0
−0.4
−0.6
−0.8
−1
Figure 2 Responsiveness of   VSRQ global score and SGRQ total score over baseline and three- month visits according to patients’ health status groups measured by A), effect 
size, B) standardized response mean, and C), Guyatt’s statistic (N = 373).
Table 5 Responsiveness to change of VSRQ and SGRQ over three 
months (N = 373)
Change in score
between V2 and V3
Global rating of healtha
Worsened
n = 53
Stable
n = 114
Improved
n = 206
VSRQ global mean score −0.82 2.38 6.66
nb (MDc) 39 (14) 89 (25) 177 (29)
SGRQ total mean score 3.08 −3.33 −9.30
nb (MDc) 48 (5) 108 (6) 198 (8)
Notes: aSubgroups deﬁ  ned from the OTE; “worsened”: all OTE scores  0, and at 
least one OTE score  −1; “stable”: all OTE scores within [−1; +1]; “improved”: all OTE 
scores  0 and at least one OTE score  1; bpatients whose global rating health and 
complete VSRQ at V2 and V3 were available; patients whose global rating health and 
SGRQ with at least 41 item completed at V2 and V3 were available; cMD, ie, patients 
whose VSRQ was incomplete at V2 and/or V3; patients whose SGRQ contained at 
least 10 missing items at V2 and/or V3.
Abbreviations: MD, missing data; OTE, Overall Treatment Effect Questionnaire; 
SGRQ, St George’s Respiratory Questionnaire; VSRQ, Visual Simpliﬁ  ed Respiratory 
Questionnaire.International Journal of COPD 2009:4 16
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The low correlation between FEV1 and VSRQ is not 
surprising. Indeed, numerous studies have shown weak 
relationship between lung function parameter measurements 
and HRQoL outcomes in COPD; such observation has also 
been reported recently for SGRQ.5,14,41 It is important to note 
that the strongest correlation was observed with the VSRQ 
dyspnea item, the most prominent symptom limiting daily 
life activities and the most frequently reported complaint of 
COPD patients. In other words, spirometry and the VSRQ as a 
HRQoL tool complement each other well to evaluate disease 
severity and the impact of treatment, eventually giving a more 
comprehensive image of the patient’s clinical condition.
Lastly, the determined MID for VSRQ was 3.4 when 
using a similar approach than Juniper and colleagues.33 
When performing a regression analysis between changes 
in VSRQ and SGRQ scores, a MID value of 3.2 for VSRQ 
was found to be corresponding to the MID value of 4 pre-
viously determined by Jones for the SGRQ.35 The close 
range of these two values is remarkable enough to be high-
lighted. The MID of VSRQ was set at 3.4. In other terms, 
scores of VSRQ needed to increase by 3.4 for a patient to 
consider their clinical status improved. In order to support 
the interpretation of VSRQ, we represented the cumulative 
response curves of changes. For the VSRQ, the determined 
median value was found to be of 3.5, again very close to 
the two previously MID values deﬁ  ned above (3.2 and 3.4). 
It would be interesting in the future to see if these MID do 
indeed predict serious clinical events such as hospitaliza-
tions or deaths.
As the VSRQ is a newly developed instrument, our ﬁ  rst 
aim was to consolidate the use and validation of the VSRQ 
in its whole. In a next step, it would be interesting to validate 
each of the items of the VSRQ by assessing their ability 
and validity to measure HRQoL when taken individually. 
The VSRQ brevity, simple scoring and good psychometric 
properties make it a good candidate for large epidemiologi-
cal studies or clinical trials, where length of completion is 
often an obstacle to the use of HRQoL questionnaires in the 
protocol. Short questionnaires such as the disease-speciﬁ  c 
Clinical COPD Questionnaire (CCQ) have not been validated 
in clinical trials evaluating inhaled therapy (corticosteroids 
and/or bronchodilators) in COPD patients yet.12 Furthermore, 
CCQ was designed to measure clinical control in COPD 
patients and does not cover all four HRQoL domains.
Patient-reported outcomes are major target of COPD 
treatment. Although this approach needs validation stud-
ies, the use of a simple HRQoL tool such as the VSRQ 
to modulate treatment in individual COPD patients might 
prove helpful. However the use of HRQoL for the clinical 
management of individual patients remains controversial, 
since the repeatability of scores is often lower than MID, 
as emphasized by Jones.40 The focusing of VSRQ ques-
tions on aims of daily life and the immediate availability 
of scores might also facilitate the communication between 
the physician and his patient about their expectations in 
treatment beneﬁ  ts. This particular issue still needs further 
validation in different clinical settings (eg, severity level) 
and in larger series. The psychometric performances of the 
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Figure 3 Cumulative response curves according to the evolution of dyspnea for the four health groups deﬁ  ned from the dyspnea Overall Treatment Effect questionnaire. 
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VSRQ should also be evaluated during pulmonary rehabili-
tation, which has a highly signiﬁ  cant impact on HRQoL.42 
Finally, it would also be interesting to investigate how the 
VSRQ performs in severely affected COPD subgroup of 
patients, particularly those with chronic respiratory failure, 
for whom new instruments are welcome.43–46
Developing and validating multi-language versions of the 
present VSRQ will be necessary to allow its implementation 
in future international clinical studies.
In conclusion, the VSRQ is now available for researchers 
and clinicians as an addition to the existing sets of HRQoL 
questionnaires. It is a promising tool for use in large real-
life studies, epidemiological and phase IV studies, as well 
as in clinical practice.7,40,47,48 However, further validation in 
speciﬁ  c studies is needed.
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